COMPANY PROFILE

Arch Oncology

Explore full profile

Arch Oncology is an immuno-oncology company

Brisbane, United StatesFounded 2006Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2021

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Arch Oncology

Arch Oncology is a biotechnology company focused on developing next-generation antibody therapeutics to treat cancer. The company specializes in creating highly differentiated anti-CD47 antibodies that not only block the 'eat signal' but also directly kill tumor cells and induce Immunogenic Cell Death (ICD). These antibodies preferentially bind to tumor cells, especially in acidic microenvironments, thereby minimizing damage to normal cells. Arch Oncology operates in the oncology market, primarily serving patients living with cancer. The business model revolves around research and development (R&D) of these advanced therapeutics, aiming to bring them through clinical trials and eventually to market. Revenue is generated through partnerships, licensing agreements, and potentially direct sales of approved therapies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2006
Headquarters: Brisbane, United States
Employees: 6
Open positions: None listed
Dealroom signal: 23.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES COther financing	Apr 2021	$105M	$420M	RiverVest Venture Partners · Adage Capital · Avego Healthcare Capital · FMB Research	—
SERIES BOther financing	Mar 2019	$50M	$200M	Lightchain Capital · Cultivation Capital · RiverVest Venture Partners · Roche Venture Fund	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Arch Oncology website traffic

Latest recorded traffic for Arch Oncology is 70 monthly website visits, down 58.8% over the last three months. Arch Oncology's team grew 0% over the past year.

Latest monthly visits70 3-month web change-58.8% 1-year team growth0%

Monthly website visitsJan 2020–Jun 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAscidian TherapeuticsEnables precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time	Boston, United States	Operational	47	$90M	$250M
ATAtalanta TherapeuticsPioneering RNAi treatments for neurodegenerative diseases	Boston, United States	Operational
CTCartesian TherapeuticsCartesian \| Developing potent, safer cell and gene therapies for cancer and autoimmune diseases - Cartesian	Gaithersburg, United States	Operational
FEFemtogenixDNA-interactive payloads for antibody-drug conjugates	St Albans, United Kingdom	Operational
ETEpics TherapeuticsDrug discovery and development company that invents and develops small molecule drugs targeting RNA epigenetic mechanisms involved in cancer development	Charleroi, Belgium	Operational
LOLocanaCreating a new class of gene therapies by targeting disease-causing messenger RNA	San Diego, United States	Operational
PIPierianDxEnables clinical labs to deliver patient-specific diagnosis and treatments	St. Louis, United States	Acquired
CICirinaAt Cirina we are pioneering products that detect cancer at its earliest stages and empower you to take action	New York City, United States	Operational